Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#CML

Home » #CML
Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Posted by By Mourabit Halima 2024.03.07
In July 2023, a study led by Professor Qian Jiang from Peking University Institute of Hematology was published in the international academic journal ——American Journal of Hematology (IF=12.8). The title…
Read More
External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy

External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy

Posted by By Mourabit Halima 2024.03.07
In September 2023, a  study led by Professor Qian Jiang from Peking University Institute of Hematology was published in the international academic journal ——Leukemia(IF=11.4). The title of the study is…
Read More
Recent Posts
  • Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC
  • ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC
  • ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm
  • ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen
  • ESMO International Perspective | Global Lung Cancer Experts Discuss the OptiTROP-Lung04 Study: Sacituzumab Tirumotecan Breaks Through Post-TKI Resistance
Recent Comments
    Archives
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top